Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KATALYST-AV: Ataciguat in Moderate Calcific Aortic Valve Stenosis
NCT07001800Phase 3Recruiting
- Sponsor
- Kardigan
- Start
- Jun 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in aortic valve stenosis comparing Ataciguat with Placebo (2 arms). Primary endpoints: Aortic Valve Calcium at 24 weeks, Aortic Valve Area at 48 weeks and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
ataciguat
03
Conditions
aortic valve stenosis
Beyond the preview
Go deeper on NCT07001800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001800.